Objective: analysis of molecular genetic phenotypes, their proliferative activity, degree of spread and differentiation of tumors in breast cancer patients affected by the accident at the Chornobyl Nuclear Power Plant.
Materials And Methods: 96 breast cancer patients who were exposed to ionizing radiation as a result of the accident at the Chornobyl Nuclear Power Plant were examined. Clinical, radiological, instrumental, morphological,immunohistochemical research methods were used.
Results And Conclusions: In patients who have been exposed to radiation, the frequency with which the moleculargenetic phenotypes of breast cancer occur is somewhat different from the generally known data. Thus, luminal Aphenotype was diagnosed in 17.7 %, luminal B in 56.2 %, HER2/neu expressing in 6.2 % and triple negative (TN)phenotype in 19.8 % patients. Proliferative activity indicators on average in patients with luminal A phenotype wereat the level of 12.7 %, luminal B - 41.5 %, triple negative - 55.6 %, and HER2/neu positive breast cancer - 32.5 %.Patients with different molecular genetic phenotypes are diagnosed with different prevalence values of the TNM criteria. Metastatic lesions of regional lymph nodes (LNs) were diagnosed in 97.9 % of patients belonging to all phenotypes of breast cancer. Ki-67 values that did not exceed 20 % were found in 22.9 % of patients, the main number -17.7 % had the luminal A subtype. In 77.1 % of patients, Ki-67 values were beyond 20 %, which indicates a moreaggressive course of the disease in the majority of patients, which included patients with various molecular genetic subtypes, except for luminal A. A high degree of differentiation of mammary gland tumors was diagnosed in 8.3% of patients. The main number of them, 6.2 %, had the luminal A phenotype. A moderate degree of differentiationwas found in 65.6 %, where 43.7 % of patients had a luminal B HER2/neu negative phenotype. A low degree of differentiation was diagnosed in 26 % of patients, among whom 12.5 % were diagnosed with TN, and 9.4 % had a luminal B HER2/neu negative phenotype.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.33145/2304-8336-2024-29-295-310 | DOI Listing |
J Transl Med
January 2025
Department of Stem Cell and Regenerative Medicine, Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Background: It is worthwhile to establish a prognostic prediction model based on microenvironment cells (MCs) infiltration and explore new treatment strategies for triple-negative breast cancer (TNBC).
Methods: The xCell algorithm was used to quantify the cellular components of the TNBC microenvironment based on bulk RNA sequencing (bulk RNA-seq) data. The MCs index (MCI) was constructed using the least absolute shrinkage and selection operator Cox (LASSO-Cox) regression analysis.
Chin Med
January 2025
Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is prevalent among patients receiving paclitaxel chemotherapy, which results in sensory abnormality as well as neuropathic pain. Conventional medications lack effectiveness on PIPN. Clinical trials identified beneficial effects of acupuncture on PIPN among patients receiving chemotherapy.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Te Aka Whai Ora (Māori Health Authority), Auckland, New Zealand.
Background: Breast cancer screening in Aotearoa New Zealand (NZ) still has persistent inequitable coverage by ethnicity, especially for Indigenous Māori women. This project aimed to undertake systematic data linkage to identify and invite eligible Māori women to participate in breast screening.
Methods: This is a cross-sectional observational study conducted in Northern New Zealand between 1/01/2020 and 30/06/2021.
Cancer Cell Int
January 2025
Department of Neurosurgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.
The tertiary lymphoid structure (TLS) is recognized as a potential prognosis factor for breast cancer and is strongly associated with response to immunotherapy. Inducing TLS neogenesis can enhance the immunogenicity of tumors and improve the efficacy of immunotherapy. However, our understanding of TLS associated region at the single-cell level remains limited.
View Article and Find Full Text PDFJ Transl Med
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, No.651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Background: HER2-targeted antibody-drug conjugates (ADCs) have revolutionized the treatment landscape of metastatic breast cancer. However, the efficacy of these therapies may be compromised by genomic alterations. Hence, this study aims to identify factors predicting sensitivity to HER2 ADC in metastatic breast cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!